Heterogeneity of driver genes and therapeutic implications in colorectal cancer

Affiliations

¹ Oncology Data Science Group, Vall D'Hebron Institute of Oncology, Barcelona, Spain Computational Oncology Group, Sage Bionetworks, Seattle, USA rdienstmann@vhio.net.
² Department Hematology and Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.

Free article

Editorial

R Dienstmann et al. Ann Oncol. 2015 Aug.

Free article

. 2015 Aug;26(8):1523-5.

doi: 10.1093/annonc/mdv229. Epub 2015 May 12.

¹ Oncology Data Science Group, Vall D'Hebron Institute of Oncology, Barcelona, Spain Computational Oncology Group, Sage Bionetworks, Seattle, USA rdienstmann@vhio.net.
² Department Hematology and Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.

No abstract available

Comment on

Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
Normanno N, Rachiglio AM, Lambiase M, Martinelli E, Fenizia F, Esposito C, Roma C, Troiani T, Rizzi D, Tatangelo F, Botti G, Maiello E, Colucci G, Ciardiello F; CAPRI-GOIM investigators. Normanno N, et al. Ann Oncol. 2015 Aug;26(8):1710-4. doi: 10.1093/annonc/mdv176. Epub 2015 Apr 7. Ann Oncol. 2015. PMID: 25851630 Clinical Trial.